Gilead Sciences, Inc.

Gilead Sciences, Inc. is an American biopharmaceutical company that discovers, develops, and commercializes medicines in HIV, liver disease, and oncology, generating $29.4 billion in total revenue in fiscal 2025. Founded in 1987 in Foster City, California, Gilead transformed the treatment of HIV and hepatitis C over three decades and now presides over the dominant antiretroviral franchise on the planet, anchored by Biktarvy, the most prescribed HIV treatment regimen in the United States with over 52% share of the domestic treatment market.

This is a story about a company that is simultaneously the incumbent in one of the most durable therapeutic franchises in pharmaceutical history and a credible challenger in oncology, cell therapy, and inflammation — all while executing the most ambitious launch cadence in its 39-year history, with up to four potential new product introductions expected before the end of 2026. The HIV business generates enormous free cash flow, has no major loss of exclusivity until 2036, and is being refreshed by a pipeline of long-acting formulations that could extend its leadership for another decade. The question is whether the rest of the portfolio — Trodelvy in breast and lung cancer, anito-cel in multiple myeloma, the Livdelzi launch in PBC, and a slate of early inflammation assets — converts enough of that cash flow into durable non-HIV growth before the market prices Gilead as a declining franchise.

The file turns on a single structural tension: the HIV business is worth something close to Gilead's entire enterprise value on a standalone basis, which means the market is assigning roughly zero to the oncology and inflammation pipelines. Whether that is deeply wrong — and whether the current management team can prove it — is what this report examines.